Literature DB >> 23661677

Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.

Shu Liu1, Zhongwen Xie, Alan Daugherty, Lisa A Cassis, Kevin J Pearson, Ming C Gong, Zhenheng Guo.   

Abstract

OBJECTIVE: Elevated plasma aldosterone concentrations in patients have been linked to a spectrum of cardiovascular diseases. Mineralocorticoid receptor antagonists provide additional benefits in patients with heart failure. However, whether aldosterone and the mineralocorticoid receptor are involved in aortic aneurysm is unknown. APPROACH AND
RESULTS: We report that administration of deoxycorticosterone acetate (DOCA) and salt or aldosterone and salt, but not DOCA or salt alone, to C57BL/6 male mice induced abdominal and thoracic aortic aneurysm formation and rupture in an age-dependent manner. DOCA and salt- or aldosterone and salt-induced aortic aneurysm mimicked human aortic aneurysm with respect to elastin degradation, inflammatory cell infiltration, smooth muscle cell degeneration and apoptosis, and oxidative stress. Aortic aneurysm formation did not correlate with the increase in blood pressure induced by DOCA and salt. Systemic administration of the angiotensin-converting enzyme inhibitor, enalapril, or angiotensin type 1 receptor antagonist, losartan, did not affect DOCA and salt-induced aortic aneurysm. In contrast, the mineralocorticoid receptor antagonists, spironolactone or eplerenone, significantly attenuated DOCA and salt- or aldosterone and salt-induced aortic aneurysm.
CONCLUSIONS: The current study describes a novel aortic aneurysm animal model induced by mineralocorticoid receptor agonist and high salt, and reveals a previously unrecognized but potentially significant role of aldosterone in the pathogenesis of aortic aneurysm. These findings imply that mineralocorticoid receptor antagonists may be effective in the treatment of some aortic aneurysms.

Entities:  

Keywords:  aldosterone; aneurysm; desoxycorticosterone; receptors; salt

Mesh:

Substances:

Year:  2013        PMID: 23661677      PMCID: PMC3707291          DOI: 10.1161/ATVBAHA.112.300820

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  34 in total

Review 1.  Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis.

Authors:  Morag J Young; Amanda J Rickard
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

Review 2.  Aldosterone: a cardiovascular risk factor?

Authors:  John W Funder; Martin Reincke
Journal:  Biochim Biophys Acta       Date:  2010-08-13

3.  Aldosterone receptor antagonists: effective but often forgotten.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

4.  Transient exposure of neonatal female mice to testosterone abrogates the sexual dimorphism of abdominal aortic aneurysms.

Authors:  Xuan Zhang; Sean E Thatcher; Debra L Rateri; Dennis Bruemmer; Richard Charnigo; Alan Daugherty; Lisa A Cassis
Journal:  Circ Res       Date:  2012-04-26       Impact factor: 17.367

5.  An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance.

Authors:  Andrew Thompson; Jackie A Cooper; Michael Fabricius; Steve E Humphries; Hilary A Ashton; Hany Hafez
Journal:  J Vasc Surg       Date:  2010-07       Impact factor: 4.268

6.  Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways.

Authors:  Alexander W Krug; Lena Allenhöfer; Robert Monticone; Gaia Spinetti; Michael Gekle; Mingyi Wang; Edward G Lakatta
Journal:  Hypertension       Date:  2010-04-26       Impact factor: 10.190

7.  Oxidation of CaMKII determines the cardiotoxic effects of aldosterone.

Authors:  B Julie He; Mei-Ling A Joiner; Madhu V Singh; Elizabeth D Luczak; Paari Dominic Swaminathan; Olha M Koval; William Kutschke; Chantal Allamargot; Jinying Yang; Xiaoqun Guan; Kathy Zimmerman; Isabella M Grumbach; Robert M Weiss; Douglas R Spitz; Curt D Sigmund; W Matthijs Blankesteijn; Stephane Heymans; Peter J Mohler; Mark E Anderson
Journal:  Nat Med       Date:  2011-11-13       Impact factor: 53.440

8.  Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice.

Authors:  Debra L Rateri; Jessica J Moorleghen; Anju Balakrishnan; A Phillip Owens; Deborah A Howatt; Venkateswaran Subramanian; Aruna Poduri; Richard Charnigo; Lisa A Cassis; Alan Daugherty
Journal:  Circ Res       Date:  2011-01-20       Impact factor: 17.367

Review 9.  Lessons on the pathogenesis of aneurysm from heritable conditions.

Authors:  Mark E Lindsay; Harry C Dietz
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

10.  Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm.

Authors:  Catherine Rush; Moses Nyara; Joseph V Moxon; Alexandra Trollope; Bradford Cullen; Jonathan Golledge
Journal:  BMC Genomics       Date:  2009-07-06       Impact factor: 3.969

View more
  25 in total

Review 1.  Monocytes and macrophages in abdominal aortic aneurysm.

Authors:  Juliette Raffort; Fabien Lareyre; Marc Clément; Réda Hassen-Khodja; Giulia Chinetti; Ziad Mallat
Journal:  Nat Rev Cardiol       Date:  2017-04-13       Impact factor: 32.419

Review 2.  Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections.

Authors:  Ying H Shen; Scott A LeMaire
Journal:  Curr Probl Surg       Date:  2017-02-03       Impact factor: 1.909

3.  Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment.

Authors:  Guido Zavatta; Guido Di Dalmazi; Carmine Pizzi; Giovanni Bracchetti; Cristina Mosconi; Caterina Balacchi; Uberto Pagotto; Valentina Vicennati
Journal:  Endocrine       Date:  2018-11-14       Impact factor: 3.633

4.  Transforming Growth Factor-β1 Inhibits Pseudoaneurysm Formation After Aortic Patch Angioplasty.

Authors:  Hualong Bai; Jung Seok Lee; Haidi Hu; Tun Wang; Toshihiko Isaji; Shirley Liu; Jianming Guo; Haiyang Liu; Katharine Wolf; Shun Ono; Xiangjiang Guo; Bogdan Yatsula; Ying Xing; Tarek M Fahmy; Alan Dardik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-16       Impact factor: 8.311

5.  Deletion of BMAL1 in Smooth Muscle Cells Protects Mice From Abdominal Aortic Aneurysms.

Authors:  Jenny Lutshumba; Shu Liu; Yu Zhong; Tianfei Hou; Alan Daugherty; Hong Lu; Zhenheng Guo; Ming C Gong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02-08       Impact factor: 8.311

Review 6.  Abdominal aortic aneurysm: novel mechanisms and therapies.

Authors:  Frank M Davis; Debra L Rateri; Alan Daugherty
Journal:  Curr Opin Cardiol       Date:  2015-11       Impact factor: 2.161

Review 7.  Role of mineralocorticoid receptor antagonists in cardiovascular disease.

Authors:  Carlos M Ferrario; Ernesto L Schiffrin
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

8.  Background differences in baseline and stimulated MMP levels influence abdominal aortic aneurysm susceptibility.

Authors:  Matthew A Dale; Melissa K Suh; Shijia Zhao; Trevor Meisinger; Linxia Gu; Vicki J Swier; Devendra K Agrawal; Timothy C Greiner; Jeffrey S Carson; B Timothy Baxter; Wanfen Xiong
Journal:  Atherosclerosis       Date:  2015-10-08       Impact factor: 5.162

9.  High Salt and IL (Interleukin)-17 in Aortic Dissection.

Authors:  Hisashi Sawada; Ming C Gong; Zhenheng Guo; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-12-23       Impact factor: 8.311

10.  P-Selectin Glycoprotein Ligand-1 Deficiency Protects Against Aortic Aneurysm Formation Induced by DOCA Plus Salt.

Authors:  Xianxian Wu; Xing Liu; Hang Yang; Qianlong Chen; Na Zhang; Yuhan Li; Xingchen Du; Xue Liu; Xiaoliang Jiang; Yideng Jiang; Zhou Zhou; Zhiwei Yang
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-11       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.